We retrospectively reviewed the medical records of patients diagnosed with MM according to the International Myeloma Working Group (IMWG) guidelines [15 (link)] at 10 medical centers in South Korea between December 2004 and June 2021. The inclusion criteria were as follows: (1) patients treated with daratumumab after more than three lines of therapy administered previously, including PI, IMiD, and/or ASCT, and (2) patients who received at least two cycles of daratumumab (total eight infusions) and underwent complete blood count (CBC) evaluation before and after daratumumab infusion. The exclusion criteria were as follows: (1) patients who received concurrent administration of other antimyeloma therapy with daratumumab and (2) patients with missing CBC values or whose treatment response was not assessed. This study was approved by the Institutional Review Board of Kyungpook National University Hospital (IRB no. 2021-05-13) and by each participating center in accordance with the Declaration of Helsinki. Written informed consent by the patients was waived due to a retrospective nature of our study.
Protocol detail
Daratumumab Therapy for Relapsed/Refractory MM
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Corresponding Organization :
Other organizations : Kyungpook National University Hospital, Ulsan University Hospital, University of Ulsan, Ulsan College, Chungnam National University Hospital, Pusan National University Hospital, Inje University Haeundae Paik Hospital, Dong-A University Hospital, Catholic University of Daegu, Keimyung University, Inje University Busan Paik Hospital, Yeungnam University Medical Center
Top 5 similar protocols
Variable analysis
independent variables
- Treatment with daratumumab after more than three lines of therapy, including PI, IMiD, and/or ASCT
- Complete blood count (CBC) evaluation before and after daratumumab infusion
- Treatment response
- Patients who received at least two cycles of daratumumab (total eight infusions)
- Patients with complete CBC values and treatment response assessed
- Negative control: Patients who received concurrent administration of other antimyeloma therapy with daratumumab (excluded)
Annotations
Based on most similar protocols
Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.
Sign up for free or login to display all annotations
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!